Moors & Cabot, Inc. Astrazeneca PLC Transaction History
Moors & Cabot, Inc.
- $2.02 Billion
- Q4 2024
A detailed history of Moors & Cabot, Inc. transactions in Astrazeneca PLC stock. As of the latest transaction made, Moors & Cabot, Inc. holds 8,091 shares of AZN stock, worth $627,861. This represents 0.03% of its overall portfolio holdings.
Number of Shares
8,091
Previous 7,191
12.52%
Holding current value
$627,861
Previous $560,000
5.36%
% of portfolio
0.03%
Previous 0.03%
Shares
34 transactions
Others Institutions Holding AZN
# of Institutions
1,367Shares Held
512MCall Options Held
6.08MPut Options Held
4.44M-
Price T Rowe Associates Inc Baltimore, MD60.4MShares$4.68 Billion0.46% of portfolio
-
Primecap Management CO Pasadena, CA41MShares$3.18 Billion2.12% of portfolio
-
Capital International Investors Los Angeles, CA37.5MShares$2.91 Billion0.48% of portfolio
-
Wellington Management Group LLP Boston, MA37MShares$2.87 Billion0.46% of portfolio
-
Bank Of America Corp Charlotte, NC24MShares$1.86 Billion0.13% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $240B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...